One of the most common neurological disorders, which occurs among 1% of the population
worldwide, is epilepsy. Therapeutic failure is common with epilepsy and nearly about 30% of patients
fall in this category. Seizure suppression should not be the only goal while treating epilepsy but associated
comorbidities, which can further worsen the condition, should also be considered. Treatment of
such comorbidities such as depression, anxiety, cognition, attention deficit hyperactivity disorder and,
various other disorders which co-exist with epilepsy or are caused due to epilepsy should also be
treated. Novel targets or the existing targets are needed to be explored for the dual mechanism which
can suppress both the disease and the comorbidity. New therapeutic targets such as IDO, nNOS, PAR1,
NF-κb are being explored for their role in epilepsy and various comorbidities. This review explores
recent therapeutic targets for the treatment of comorbidities associated with epilepsy.
Dual mechanism for the control of inducible-type NO synthase gene expression in macrophages during activation by interferon-gamma and bacterial lipopolysaccharide. Transcriptional and post-transcriptional regulation.
